Effect of SGLT2 Inhibitors on Organ Support–Free Survival in Patients Hospitalised for COVID-19
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Diabetes & Endocrinology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Effect of sodium-glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, platform trial
Lancet Diabetes Endocrinol 2024 Sep 05;[EPub Ahead of Print], MN Kosiborod, SL Windsor, O Vardeny, JS Berger, HR Reynolds, S Boumakis, AD Althouse, SD Solomon, AS Bhatt, A Peikert, JF Luther, ES Leifer, AL Kindzelski, M Cushman, M Ng Gong, LZ Kornblith, P Khatri, KS Kim, L Baumann Kreuziger, A Javaheri, C Carpio, L Wahid, J Lopez-Sendon Moreno, A Alonso, MQ Ho, J Lopez-Sendon, RD Lopes, JL Curtis, BA Kirwan, MW Geraci, MD Neal, JS HochmanFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.